Workshop on Future Opportunities for
Combination Biological Therapy of Cancer

November 1, 2007
Seaport World Trade Center
Boston, Massachusetts

Workshop Schedule (subject to change)

8:00 am - 8:15 am	Welcome and Meeting Introduction Jon M. Wigginton, MD - Merck & Co., Inc.
8:15 am - 11:30 am	State of the Science (*) indicates presenting co-chair Moderator: Thomas F. Gajewski, MD, PhD - University of Chicago
8:15 am - 9:00 am	Immunotherapy and Immunotherapy Combinations Co-Chairs: Thomas F. Gajewski, MD, PhD - University of Chicago (*) Jon M. Wigginton, MD - Merck & Co., Inc. Panelists: Lieping Chen, MD, PhD - Johns Hopkins University School of Medicine Glenn Dranoff, MD - Dana-Farber Cancer Institute
9:00 am - 9:45 am	Angiogenesis and Immunotherapy Combinations Co-Chairs: George Coukos, MD, PhD - University of Pennsylvania Medical Center (*) Heinz Zwierzina, MD - Innsbruck Medical University Panelists: Michael B. Atkins, MD - Beth Israel Deaconess Medical Center Steven K. Libutti, MD - National Cancer Institute Robert M. Strieter, MD - University of Virginia School of Medicine
9:45 am - 10:00 am	BREAK
10:00 am - 10:45 am	Apoptosis Induction and Immunotherapy Co-Chairs: James H. Finke, PhD - Cleveland Clinic Foundation Peter Hersey, MD, PhD - University of Newcastle (*) Panelists: Douglas R. Green, PhD - St. Jude Children's Research Hospital James W. Mier, MD - Beth Israel Deaconess Medical Center
10:45 am - 11:30 am	Cytotoxic Chemotherapy and Immunotherapy Co-Chairs: Hyam I. Levitsky, MD - Johns Hopkins University School of Medicine (*) Ronald E. Gress, MD - NCI, NIH Panelists: Bruce Blazar, MD - University of Minnesota Leisha A. Emens, MD, PhD - Johns Hopkins University
11:30 am - 12:00 pm	Lunch
12:00 pm - 1:30 pm	Concurrent Session: Breakout Sessions (*) indicates the co-chair leading the session (Pre-registration and ticket required for all breakout sessions)
	Breakout 1: Immunotherapy and Immunotherapy Combinations (Green ticket required) Co-Chairs: Thomas F. Gajewski, MD, PhD - University of Chicago Jon M. Wigginton, MD - Merck & Co., Inc. (*) Breakout 2: Angiogenesis and Immunotherapy Combinations (Yellow ticket required) Co-Chairs: George Coukos, MD, PhD - University of Pennsylvania Medical Center Heinz Zwierzina, MD - Innsbruck Medical University (*) Breakout 3: Apoptosis Induction and Immunotherapy (Blue ticket required) Co-Chairs: James H. Finke, PhD - Cleveland Clinic Foundation (*) Peter Hersey, MD, PhD - University of Newcastle Breakout 4: Cytotoxic Chemotherapy and Immunotherapy (Red ticket required) Co-Chairs: Hyam I. Levitsky, MD - Johns Hopkins University School of Medicine Ronald E. Gress, MD - NCI, NIH (*)
12:00 pm - 1:30 pm	Concurrent Group Lecture: Abstract Presentations Co-Chairs: Anne Letsch, MD - Chaité, Campus Benjamin Franklin David F. McDermott, MD - Beth Israel Deaconess Medical Center
12:00 PM - 12:15 PM	Anti-PD-1 Antibody Enhances the Potency of GM-CSF-Secreting Tumor Cell Immunotherapies by Augmenting Immunotherapy-Induced Tumor-Specific T-Cell Responses Betty Li - Cell Genesys, Inc.
12:15 PM - 12:30 PM	Expression of VEGFR-2 by Human Melanoma Cells Confers Synergistic Inhibition of Proliferations by Avastin and Rapamycin Kerrington R. Molhoek, PhD - University of Virginia
12:30 PM - 12:45 PM	The Raf Kinase Inhibitor Sorafenib Inhibits Jak-STAT Signal Transduction in Human Immune Cells Ene T. Raig - The Ohio State University
12:45 PM - 1:00 PM	Cyclophosphamide and Fludarabine Treatment Prior to Reconstitution with PBMC Does Not Reduce the Frequency of Circulating FoxP3+ Cells in Vaccinated Prostate Cancer Patients James Thompson, PhD - Earle A. Chiles Research Institute
1:00 PM - 1:15 PM	Treatment of Established Tumors with Peritumoral Injections of CD40 Ligand (CD40L), CpG, poly(I:C), and Extracellular ATP in Murine Models Richard S. Kornbluth, MD, PhD - University of California San Diego
1:15 PM - 1:30 PM	GITR Ligation and CD4+ T-Cell Combination Therapy Eradicates an Aggressive Solid Tumor by Concomitantly Enhancing Antitumor Immunity While Inhibiting Treg Suppressive Activity Zhaoyang You, PhD - University of Pittsburgh School of Medicine
1:30 pm - 1:45 pm	BREAK
1:45 pm - 2:45 pm	Plenary Session: Perspectives on Combination Therapy Moderator: Bernard A. Fox, PhD - Earle A. Chiles Research Institute
	Regulatory Perspective Speaker: Ashok Batra, MD - Food and Drug Administration
	Industry Perspective Speaker: Geoffrey M. Nichol, MBChB, MBA - Medarex, Inc
	Legal Perspective Speaker: Andrew D. Barofsky, JD, MBA - Oregon Biomedical Engineering Institute, Inc.
2:45 pm - 4:45 pm	Breakout Session Reports/Panel Discussions Moderator: Rachel W. Humphrey, MD - Bristol-Myers Squibb
2:45 pm - 3:15 pm	Breakout 1 Report: Immunotherapy and Immunotherapy Combinations Jon M. Wigginton, MD - Merck & Co., Inc.
3:15 pm - 3:45 pm	Breakout 2 Report: Angiogenesis and Immunotherapy Combinations Heinz Zwierzina, MD - Innsbruck Medical University
3:45 pm - 4:15 pm	Breakout 3 Report: Apoptosis Induction and Immunotherapy James H. Finke, PhD - Cleveland Clinic Foundation
4:15 pm - 4:45 pm	Breakout 4 Report: Cytotoxic Chemotherapy and Immunotherapy Ronald E. Gress, MD - NCI, NIH
4:45 pm - 5:00 pm	Closing Comment and Future Plans

International Society for Biological Therapy of Cancer
555 East Wells Street, Suite 1100
Milwaukee, Wisconsin 53202-3823
Ph: 414-271-2456
E-Mail: info@isbtc.org

©2008 iSBTc
All rights reserved